section name header

Pronunciation

DOX-a-pram

Classifications

Therapeutic Classification: central nervous system stimulants

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Administered IV only; results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Rapidly metabolized; metabolites mostly excreted by the kidneys.

Half-life: 2.4–4 hr.

Time/Action Profile

(increases in minute volume)

ROUTEONSETPEAKDURATION
IV20–40 sec1–2 min5–12 min

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension, T-wave inversion, arrhythmias, changes in heart rate, chest pain.

Derm: flushing, pruritus, sweating.

EENT: gagging, mydriasis.

GI: diarrhea, nausea, vomiting.

GU: urinary retention, albuminuria, perineal/genital burning sensation, spontaneous voiding.

Hemat: hemolysis.

Local: phlebitis.

MS: muscle spasticity, involuntary movement, skeletal muscle hyperactivity.

Neuro: apprehension, disorientation, dizziness, generalized clonus, headache, paresthesia, positive bilateral Babinski’s sign , SEIZURES.

Resp: bronchospasm, cough, dyspnea, hiccups, LARYNGOSPASM, rebound hypoventilation, tachypnea.
Misc: fever.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Respiratory Depression following Anesthesia

Drug-Induced CNS Depression

Acute Hypercapnea Secondary to COPD

Availability

Assessment

Lab Test Considerations: Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Dopram